HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.0%

Neg 0% Neu 89% Pos 0%

HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $35 price target.